Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
BCRX
Strong BuyFull HouseFLAGBioCryst Pharmaceuticals, Inc. · Healthcare · United States · $2.5B · Avg Vol: $29M/d
BioCryst has strong momentum at M76 and a 36.0% upward revision, but quality Q53 and value V52 both sit just above the floor and miss the all-three-above-60 path, and a positive revision is not one of the two accepted corroborating signals.
COMPANY DESCRIPTION
BioCryst Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing oral, small-molecule medicines for patients with rare diseases. Its competitive moat is anchored by ORLADEYO, a proprietary oral drug offering a differentiated and convenient treatment for hereditary angioedema (HAE). BioCryst leverages its expertise in small-molecule drug development to address high unmet needs in niche patient populations.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 270.8M | 331.4M | 450.7M | 874.8M | 47.8% | 940.6M | 702.2M | 737.3M | -8.2% |
| EPS | -1.33 | -1.18 | -0.43 | 1.26 | — | -1.40 | 1.48 | 1.87 | 21.7% |
| Shares | 187.9M | 205.8M | 208.5M | 213.1M | +13.4% | 255.5M | — | — | — |
| Debt | 741.5M | 825.1M | 808.7M | 438.9M | -16.0% | 836.6M | — | — | — |
| Equity | -294.6M | -455.5M | -475.9M | -119.2M | — | — | — | — | — |
| Op CF | -161.8M | -95.1M | -52.0M | 347.4M | — | 376.1M | — | — | — |
| Inv CF | -128.2M | -131.5M | 52.6M | -13.7M | — | — | — | — | — |
| Fin CF | 88.0M | 32.5M | -5.8M | -349.9M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BCRX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| BCRX | BioCryst Pharmaceuticals, Inc.(you) | $2.5B | 85 | Strong Buy |
| TRLV | Trulieve Cannabis Corp. | $2.3B | 90 | Strong Buy |
| ANIP | ANI Pharmaceuticals, Inc. | $1.7B | 92 | Strong Buy |
| PBH | Prestige Consumer Healthcare Inc. | $2.5B | 67 | Buy |
| PCRX | Pacira BioSciences, Inc. | $1.0B | 85 | Strong Buy |
| GTII.CN | Green Thumb Industries Inc. | $1.6B | 94 | Strong Buy |
| INDV | Indivior Pharmaceuticals, Inc. | $4.1B | 94 | Strong Buy |
| AMRX | Amneal Pharmaceuticals, Inc. | $6.1B | 83 | Strong Buy |
| ETON | Eton Pharmaceuticals, Inc. | $1.7B | 72 | Buy |
| PAHC | Phibro Animal Health Corporation | $1.5B | 74 | Buy |
Peer medians: ROE -30.7% · P/E 27.0x · Gross margin 58.1%